Product Description
Mechanisms of Action: STAT3 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shanghai Yuyao Biotech
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for YY201](https://pryzm-maps.s3.us-west-2.amazonaws.com/12current_maps.png)
Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Large Granular Lymphocytic Leukemia|Lymphoid Leukemia|Relapsed/Refractory Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2022-YY201-CH1 | P1 |
Recruiting |
Large Granular Lymphocytic Leukemia|Relapsed/Refractory Lymphoma|Lymphoid Leukemia |
2026-12-30 |